

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)  
Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 2<sup>nd</sup> February, 2023

**CORRIGENDUM**

S.O. 488(E). — In the National Pharmaceutical Pricing Authority's notification S.O. 4884(E), dated 26<sup>th</sup> November, 2021 relating to fixation of retail price, published in the Gazette of India, Extraordinary, the Entry at Sl. No. 42 of the Table, both in Hindi & English version, be read as follows:

Instead of

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
42	Formoterol Fumarate + Budesonide Powder for Inhalation	Each hard gelatin capsule contains: Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 12mcg Budesonide IP 400mcg	1 Capsule	M/s Biodeal Pharmaceuticals Pvt. Ltd./ M/s Mankind Pharma Limited	7.10

Read as

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
42	Formoterol Fumarate + Budesonide Powder for Inhalation	Each hard gelatin capsule contains: Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 12mcg Budesonide IP 400mcg	1 Capsule	M/s Biodeal Pharmaceuticals Pvt. Ltd./ M/s Mankind Pharma Limited	9.35

All the notes and other contents mentioned in the original order S.O. 4884(E), dated 26<sup>th</sup> November, 2021 shall remain same.

PN/237/105/2022/F

F. No. 8(105)/2022/D.P./NPPA-Div.-II

(Mahaveer Saini)  
Deputy Director